314 related articles for article (PubMed ID: 35012639)
21. Systematic druggable genome-wide Mendelian randomisation identifies therapeutic targets for Alzheimer's disease.
Su WM; Gu XJ; Dou M; Duan QQ; Jiang Z; Yin KF; Cai WC; Cao B; Wang Y; Chen YP
J Neurol Neurosurg Psychiatry; 2023 Nov; 94(11):954-961. PubMed ID: 37349091
[TBL] [Abstract][Full Text] [Related]
22. Population-based discovery and Mendelian randomization analysis identify telmisartan as a candidate medicine for Alzheimer's disease in African Americans.
Zhang P; Hou Y; Tu W; Campbell N; Pieper AA; Leverenz JB; Gao S; Cummings J; Cheng F
Alzheimers Dement; 2023 May; 19(5):1876-1887. PubMed ID: 36331056
[TBL] [Abstract][Full Text] [Related]
23. Genetic insights into immune mechanisms of Alzheimer's and Parkinson's disease.
Nott A; Holtman IR
Front Immunol; 2023; 14():1168539. PubMed ID: 37359515
[TBL] [Abstract][Full Text] [Related]
24. Integration of Alzheimer's disease genetics and myeloid genomics identifies disease risk regulatory elements and genes.
Novikova G; Kapoor M; Tcw J; Abud EM; Efthymiou AG; Chen SX; Cheng H; Fullard JF; Bendl J; Liu Y; Roussos P; Björkegren JL; Liu Y; Poon WW; Hao K; Marcora E; Goate AM
Nat Commun; 2021 Mar; 12(1):1610. PubMed ID: 33712570
[TBL] [Abstract][Full Text] [Related]
25. The Alzheimer's Cell Atlas (TACA): A single-cell molecular map for translational therapeutics accelerator in Alzheimer's disease.
Zhou Y; Xu J; Hou Y; Bekris L; Leverenz JB; Pieper AA; Cummings J; Cheng F
Alzheimers Dement (N Y); 2022; 8(1):e12350. PubMed ID: 36254161
[TBL] [Abstract][Full Text] [Related]
26. Medical genetics-based drug repurposing for Alzheimer's disease.
Zhang XZ; Quan Y; Tang GY
Brain Res Bull; 2015 Jan; 110():26-9. PubMed ID: 25446738
[TBL] [Abstract][Full Text] [Related]
27. Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease.
Fang J; Zhang P; Zhou Y; Chiang CW; Tan J; Hou Y; Stauffer S; Li L; Pieper AA; Cummings J; Cheng F
Nat Aging; 2021 Dec; 1(12):1175-1188. PubMed ID: 35572351
[TBL] [Abstract][Full Text] [Related]
28. Single-cell network biology characterizes cell type gene regulation for drug repurposing and phenotype prediction in Alzheimer's disease.
Gupta C; Xu J; Jin T; Khullar S; Liu X; Alatkar S; Cheng F; Wang D
PLoS Comput Biol; 2022 Jul; 18(7):e1010287. PubMed ID: 35849618
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic Mechanism of Kai Xin San on Alzheimer's Disease Based on Network Pharmacology and Experimental Validation.
Wang K; Yang R; Chen TT; Qin MR; Wang P; Kong MW
Chin J Integr Med; 2023 May; 29(5):413-423. PubMed ID: 36474082
[TBL] [Abstract][Full Text] [Related]
30. Pathogenesis, therapeutic strategies and biomarker development based on "omics" analysis related to microglia in Alzheimer's disease.
Gao C; Shen X; Tan Y; Chen S
J Neuroinflammation; 2022 Sep; 19(1):215. PubMed ID: 36058959
[TBL] [Abstract][Full Text] [Related]
31. Microglia - mediated immunity partly contributes to the genetic association between Alzheimer's disease and hippocampal volume.
Lancaster TM; Hill MJ; Sims R; Williams J
Brain Behav Immun; 2019 Jul; 79():267-273. PubMed ID: 30776473
[TBL] [Abstract][Full Text] [Related]
32. Linking Alzheimer's disease and type 2 diabetes: Novel shared susceptibility genes detected by cFDR approach.
Wang XF; Lin X; Li DY; Zhou R; Greenbaum J; Chen YC; Zeng CP; Peng LP; Wu KH; Ao ZX; Lu JM; Guo YF; Shen J; Deng HW
J Neurol Sci; 2017 Sep; 380():262-272. PubMed ID: 28870582
[TBL] [Abstract][Full Text] [Related]
33. Identifying the Association Between Alzheimer's Disease and Parkinson's Disease Using Genome-Wide Association Studies and Protein-Protein Interaction Network.
Liu G; Bao X; Jiang Y; Liao M; Jiang Q; Feng R; Zhang L; Ma G; Chen Z; Wang G; Wang R; Zhao B; Li K
Mol Neurobiol; 2015 Dec; 52(3):1629-1636. PubMed ID: 25370933
[TBL] [Abstract][Full Text] [Related]
34. Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining.
Zhang M; Schmitt-Ulms G; Sato C; Xi Z; Zhang Y; Zhou Y; St George-Hyslop P; Rogaeva E
PLoS One; 2016; 11(12):e0168812. PubMed ID: 28005991
[TBL] [Abstract][Full Text] [Related]
35. Mapping the gene network landscape of Alzheimer's disease through integrating genomics and transcriptomics.
Rosenthal SB; Wang H; Shi D; Liu C; Abagyan R; McEvoy LK; Chen CH
PLoS Comput Biol; 2022 Feb; 18(2):e1009903. PubMed ID: 35213535
[TBL] [Abstract][Full Text] [Related]
36. Repositioning drugs by targeting network modules: a Parkinson's disease case study.
Yue Z; Arora I; Zhang EY; Laufer V; Bridges SL; Chen JY
BMC Bioinformatics; 2017 Dec; 18(Suppl 14):532. PubMed ID: 29297292
[TBL] [Abstract][Full Text] [Related]
37. Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer's disease.
Rangaraju S; Dammer EB; Raza SA; Rathakrishnan P; Xiao H; Gao T; Duong DM; Pennington MW; Lah JJ; Seyfried NT; Levey AI
Mol Neurodegener; 2018 May; 13(1):24. PubMed ID: 29784049
[TBL] [Abstract][Full Text] [Related]
38. Functional enrichment analysis of three Alzheimer's disease genome-wide association studies identities DAB1 as a novel candidate liability/protective gene.
Gao H; Tao Y; He Q; Song F; Saffen D
Biochem Biophys Res Commun; 2015 Aug; 463(4):490-5. PubMed ID: 26028559
[TBL] [Abstract][Full Text] [Related]
39. Artificial intelligence-based computational framework for drug-target prioritization and inference of novel repositionable drugs for Alzheimer's disease.
Tsuji S; Hase T; Yachie-Kinoshita A; Nishino T; Ghosh S; Kikuchi M; Shimokawa K; Aburatani H; Kitano H; Tanaka H
Alzheimers Res Ther; 2021 May; 13(1):92. PubMed ID: 33941241
[TBL] [Abstract][Full Text] [Related]
40. Protein-Protein interactions uncover candidate 'core genes' within omnigenic disease networks.
Ratnakumar A; Weinhold N; Mar JC; Riaz N
PLoS Genet; 2020 Jul; 16(7):e1008903. PubMed ID: 32678846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
